{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T21:58:59Z","timestamp":1775685539026,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Case Reports"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jaccas.2026.107035","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T12:53:53Z","timestamp":1772628833000},"page":"107035","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of Mavacamten Therapy on Myocardial Systolic Function Assessed by 3D Echocardiography"],"prefix":"10.1016","volume":"31","author":[{"given":"Roberto","family":"Polizzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grazia","family":"Canciello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5877-2090","authenticated-orcid":false,"given":"Leopoldo","family":"Ordine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0565-7127","authenticated-orcid":false,"given":"Giovanni","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Angela","family":"Losi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccas.2026.107035_bib1","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccas.2026.107035_bib2","doi-asserted-by":"crossref","first-page":"E8143","DOI":"10.1073\/pnas.1809540115","article-title":"Deciphering the super relaxed state of human beta-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers","volume":"115","author":"Anderson","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaccas.2026.107035_bib3","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaccas.2026.107035_bib4","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.124.012441","article-title":"Mavacamten: real-world experience from 22 months of the risk evaluation and mitigation strategy (REMS) program","volume":"18","author":"Desai","year":"2025","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jaccas.2026.107035_bib5","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.125.044537","article-title":"World observations in patients with obstructive hypertrophic cardiomyopathy treated with mavacamten: evidence of favorable disease modification","volume":"14","author":"Desai","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jaccas.2026.107035_bib6","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1093\/eurheartj\/ehad637","article-title":"Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy","volume":"44","author":"Braunwald","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccas.2026.107035_bib7","article-title":"Reverse septal curvature in hypertrophic cardiomyopathy: implications for function, structure and arrhythmic risk","volume":"444","author":"Polizzi","year":"2025","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jaccas.2026.107035_bib8","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1161\/01.CIR.88.5.2206","article-title":"Regional left ventricular mechanics in hypertrophic cardiomyopathy","volume":"88","author":"Betocchi","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.jaccas.2026.107035_bib9","doi-asserted-by":"crossref","first-page":"H610","DOI":"10.1152\/ajpheart.2001.280.2.H610","article-title":"Regional nonuniformity of normal adult human left ventricle","volume":"280","author":"Bogaert","year":"2001","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jaccas.2026.107035_bib10","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"}],"container-title":["JACC: Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666084926001828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666084926001828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T20:55:29Z","timestamp":1775681729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666084926001828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":10,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2666084926001828"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccas.2026.107035","relation":{},"ISSN":["2666-0849"],"issn-type":[{"value":"2666-0849","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Mavacamten Therapy on Myocardial Systolic Function Assessed by 3D Echocardiography","name":"articletitle","label":"Article Title"},{"value":"JACC: Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccas.2026.107035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"107035"}}